HER2-Positive Advanced Gastro-Esophageal and GI CancersPhase 1NCT05274048
Neratinib + Trastuzumab Deruxtecan
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
What the film says
This trial is for stomach cancer that has spread to the peritoneum, the lining of the abdomen.
The idea: put the treatment where the cancer is. Natural killer cells, immune cells from donated cord blood, are engineered to recognize TROP2 and to carry the signal IL-15. One more gene, for the TGF-beta receptor 2, is switched off.
After a minimally invasive staging surgery, the cells are infused straight into the abdomen through a port. The first question is safety and the best dose. At MD Anderson in Houston, Brian Badgwell leads this early study.
Public record; not medical advice.
Sources behind this film
Stomach cancer spread to the peritoneum; NK cells from donated cord blood, engineered for TROP2 and IL-15; TGFBR2 knocked out; Staging surgery, port, cells infused into the abdomen; First question is safety and best dose (+1 more lines)
The drug
Primary Objectives: To determine the safety, MTD, and RP2D of TROP2 CAR/IL-15 TGFBR2 KO NK cells delivered intraperitoneally and define the MTD/RP2D. Endpoints 1. Dose-limiting toxicity 2. MTD and RP2D of TROP2 CAR/IL-15 TGFBR2 KO NK cells Secondary Objectives: 1. To estimate median overall survival. 2. To quantify persistence of infused allogeneic donor CAR-transduced CB-derived NK cells in the peripheral blood and peritoneal cavity in the recipient. 3.
To profile and assess the dynamic changes in the peritoneal tumor microenvironment before and after treatment using single-cell transcriptional and immune profiling on peritoneal cells before and after treatment. 4. To compare changes in circulating tumor DNA (ctDNA) with response as determined by the peritoneal carcinomatosis index Endpoints 1. Median overall survival 2. TROP2 CAR/IL-15 TGFBR2 KO NK cells numbers in peripheral blood and peritoneal cavity vs time profile 3.
The study
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.